Short Interest in Nanobiotix S.A. (NASDAQ:NBTX) Increases By 37.6%

Nanobiotix S.A. (NASDAQ:NBTX) was the target of a large increase in short interest in February. As of February 28th, there was short interest totalling 29,300 shares, an increase of 37.6% from the February 13th total of 21,300 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average daily trading volume, of 32,500 shares, the short-interest ratio is currently 0.9 days.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC bought a new stake in shares of Nanobiotix during the fourth quarter worth about $29,000. Millennium Management LLC bought a new stake in shares of Nanobiotix during the 4th quarter worth $39,000. Jane Street Group LLC bought a new stake in Nanobiotix in the fourth quarter worth about $73,000. Finally, OLD Mission Capital LLC bought a new stake in Nanobiotix in the fourth quarter worth about $139,000. Institutional investors own 38.81% of the company’s stock.

Nanobiotix Trading Up 11.9 %

Shares of NBTX stock traded up $0.40 on Tuesday, hitting $3.75. The company’s stock had a trading volume of 18,429 shares, compared to its average volume of 21,971. The stock’s 50 day moving average is $3.44 and its 200-day moving average is $3.94. Nanobiotix has a fifty-two week low of $2.76 and a fifty-two week high of $7.51.

Wall Street Analysts Forecast Growth

Separately, UBS Group raised Nanobiotix to a “hold” rating in a research note on Monday, February 17th.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.